Literature DB >> 1503554

The molecular basis of the type 1 glycogen storage diseases.

A Burchell1.   

Abstract

Microsomal glucose-6-phosphatase catalyses the last step in liver glucose production. Glucose-6-phosphatase deficiency, now termed type 1 glycogen storage disease, was first described almost 40 years ago but until recently very little was known about the molecular basis of the various type 1 glycogen storage diseases. Recently we have shown that at least six different proteins are needed for normal glucose-6-phosphatase activity in liver. Four of the proteins have been purified and three cloned. Study of the type 1 glycogen storage diseases has stimulated investigations of the mechanisms of small molecule transport across the endoplasmic reticulum membrane and demonstrated the existence of novel endoplasmic reticulum transport proteins for glucose and phosphate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1503554     DOI: 10.1002/bies.950140609

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  15 in total

1.  Therapeutic insulin and hepatic glucose-6-phosphatase activity in preterm infants.

Authors:  A Burchell; A McGeechan; R Hume
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

2.  Urinary lactate excretion in type 1 glycogenosis--a marker of metabolic control or renal tubular dysfunction?

Authors:  P J Lee; C Chatterton; J V Leonard
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

3.  Immunohistochemical localisation of glucose-6-phosphatase in developing human kidney.

Authors:  R Hume; J E Bell; A Hallas; A Burchell
Journal:  Histochemistry       Date:  1994-07

4.  Glomerular and tubular function in glycogen storage disease.

Authors:  P J Lee; R N Dalton; V Shah; P C Hindmarsh; J V Leonard
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

5.  Bone mineralisation in type 1 glycogen storage disease.

Authors:  P J Lee; J S Patel; M Fewtrell; J V Leonard; N J Bishop
Journal:  Eur J Pediatr       Date:  1995-06       Impact factor: 3.183

6.  The hepatic glucose-6-phosphatase system in Ehrlich-ascites-tumour-bearing mice.

Authors:  R W Lucius; I D Waddell; A Burchell; R C Nordlie
Journal:  Biochem J       Date:  1993-03-15       Impact factor: 3.857

7.  Multiple transport protein defects in a patient with glycogen storage disease type 1: GSD 1b/1c beta.

Authors:  R A Hawkins; K R Kamath; H M Scott; A Burchell
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

8.  Transforming growth factor-beta in renal disease with glycogen storage disease I.

Authors:  Maki Urushihara; Shoji Kagami; Michinori Ito; Koji Yasutomo; Shuji Kondo; Akiko Kitamura; Akiyoshi Takahashi; Yasuhiro Kuroda
Journal:  Pediatr Nephrol       Date:  2004-04-03       Impact factor: 3.714

9.  The human embryonic-fetal kidney endoplasmic reticulum phosphate-pyrophosphate transport protein.

Authors:  R Hume; H Brewerton; A Burchell
Journal:  Virchows Arch       Date:  1996-03       Impact factor: 4.064

10.  Fatty acyl-CoA esters inhibit glucose-6-phosphatase in rat liver microsomes.

Authors:  R Fulceri; A Gamberucci; H M Scott; R Giunti; A Burchell; A Benedetti
Journal:  Biochem J       Date:  1995-04-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.